{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:54:19Z","timestamp":1790963659100,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["ESTDAB-039"],"award-info":[{"award-number":["ESTDAB-039"]}],"id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["244388"],"award-info":[{"award-number":["244388"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["254817"],"award-info":[{"award-number":["254817"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2016006"],"award-info":[{"award-number":["2016006"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2017075"],"award-info":[{"award-number":["2017075"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ymthe.2020.11.019","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:06:39Z","timestamp":1605560799000},"page":"1199-1213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Pierre","family":"Dillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"K\u00f6ksal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solrun Melkorka","family":"Maggadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Winge-Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Pollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit Ren\u00e9e","family":"Myhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild M.","family":"M\u00e6landsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi Ann","family":"Fl\u00f8renes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Gaudernack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kvalheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"W\u00e4lchli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-3536","authenticated-orcid":false,"given":"Else Marit","family":"Inderberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.11.019_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.11.019_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.11.019_bib3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrclinonc.2016.67","article-title":"A second chance for telomerase reverse transcriptase in anticancer immunotherapy","volume":"14","author":"Zanetti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1101\/SQB.1994.059.01.035","article-title":"Telomerase, cell immortality, and cancer","volume":"59","author":"Harley","year":"1994","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.019_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B","article-title":"Telomerase in human development and cancer","volume":"173","author":"Shay","year":"1997","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/JTO.0b013e3181886713","article-title":"Telomeres and telomerase in lung cancer","volume":"3","author":"Fernandez-Garcia","year":"2008","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib9","doi-asserted-by":"crossref","first-page":"80139","DOI":"10.18632\/oncotarget.20960","article-title":"Telomere DNA damage signaling regulates cancer stem cell evolution, epithelial mesenchymal transition, and metastasis","volume":"8","author":"Lagunas","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2020.11.019_bib10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1101\/gad.451008","article-title":"The longest telomeres: a general signature of adult stem cell compartments","volume":"22","author":"Flores","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2020.11.019_bib11","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1016\/j.febslet.2010.07.042","article-title":"The role of telomeres and telomerase in stem cell aging","volume":"584","author":"Flores","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2020.11.019_bib12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.019_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T\u00a0cells in synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2020.11.019_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.019_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2020.11.019_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T\u00a0cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.019_bib17","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00262-006-0145-7","article-title":"Telomerase peptide vaccination: a phase I\/II study in patients with non-small cell lung cancer","volume":"55","author":"Brunsvig","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2020.11.019_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4161\/onci.20426","article-title":"Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001","volume":"1","author":"Inderberg-Suso","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib19","doi-asserted-by":"crossref","first-page":"e98791","DOI":"10.1172\/jci.insight.98791","article-title":"Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas","volume":"3","author":"M\u00fcller","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2020.11.019_bib20","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.4049\/jimmunol.169.12.6928","article-title":"HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity","volume":"169","author":"Castelli","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib21","unstructured":"(1996). 12th International Histocompatibility Conference. Genetic diversity of HLA: functional and medical implications. Paris, France, June 9-12, 1996. Abstracts. Hum. Immunol. 47, 1\u2013184."},{"key":"10.1016\/j.ymthe.2020.11.019_bib22","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0903655","article-title":"Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity","volume":"184","author":"Sidney","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib23","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","article-title":"Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I\/II study","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2020.11.019_bib24","doi-asserted-by":"crossref","first-page":"e1249090","DOI":"10.1080\/2162402X.2016.1249090","article-title":"T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy","volume":"5","author":"Kyte","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib25","doi-asserted-by":"crossref","first-page":"e1565236","DOI":"10.1080\/2162402X.2019.1565236","article-title":"Transient redirection of T\u00a0cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination","volume":"8","author":"Kyte","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00205442","article-title":"Importance of MHC antigen expression on solid tumors in the in\u00a0vitro interaction with autologous blood lymphocytes","volume":"27","author":"V\u00e1nky","year":"1988","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2020.11.019_bib27","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.4049\/jimmunol.181.11.7843","article-title":"MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes","volume":"181","author":"Robila","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00262-019-02468-9","article-title":"Long-term surviving cancer patients as a source of therapeutic TCR","volume":"69","author":"Inderberg","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2020.11.019_bib29","doi-asserted-by":"crossref","first-page":"e27930","DOI":"10.1371\/journal.pone.0027930","article-title":"A practical approach to T-cell receptor cloning and expression","volume":"6","author":"W\u00e4lchli","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.11.019_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00262-009-0810-8","article-title":"CD34-based enrichment of genetically engineered human T\u00a0cells for clinical use results in dramatically enhanced tumor targeting","volume":"59","author":"Norell","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2020.11.019_bib31","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4049\/jimmunol.1700242","article-title":"Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations","volume":"200","author":"Rius","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/14653249.2010.542461","article-title":"Transiently redirected T\u00a0cells for adoptive transfer","volume":"13","author":"Alm\u00e5sbak","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2020.11.019_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4049\/jimmunol.1202591","article-title":"Immunotherapy with TCR-redirected T\u00a0cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T\u00a0cells","volume":"192","author":"St\u00e4rck","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib34","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","article-title":"Facilitating matched pairing and expression of TCR chains introduced into human T\u00a0cells","volume":"109","author":"Kuball","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.019_bib35","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.168.11.5954","article-title":"Characterization of CD4(+) CTLs ex\u00a0vivo","volume":"168","author":"Appay","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib36","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.11.019_bib37","doi-asserted-by":"crossref","first-page":"1558663","DOI":"10.1080\/2162402X.2018.1558663","article-title":"Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T\u00a0cell immunity","volume":"8","author":"Mensali","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib38","first-page":"3630","article-title":"Generation of NY-ESO-1-specific CD4+ and CD8+ T\u00a0cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design","volume":"62","author":"Zeng","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.11.019_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/j.1460-2075.1995.tb06973.x","article-title":"How MHC class II molecules reach the endocytic pathway","volume":"14","author":"B\u00e9naroch","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2020.11.019_bib40","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma","volume":"3","author":"K\u00f6ksal","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2020.11.019_bib41","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00262-019-02356-2","article-title":"Preclinical assessment of transiently TCR redirected T\u00a0cells for solid tumour immunotherapy","volume":"68","author":"Mensali","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2020.11.019_bib42","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1073\/pnas.92.20.9082","article-title":"Telomerase activity in normal and malignant hematopoietic cells","volume":"92","author":"Broccoli","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.019_bib43","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.4049\/jimmunol.155.8.3711","article-title":"Activation of telomerase in human lymphocytes and hematopoietic progenitor cells","volume":"155","author":"Hiyama","year":"1995","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib44","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.immuni.2013.08.036","article-title":"A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T\u00a0cells","volume":"39","author":"Huang","year":"2013","journal-title":"Immunity"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.019_bib45","first-page":"4451","article-title":"A Direct Comparison of the In\u00a0Vivo Efficacy and in\u00a0Vitro Signaling of Chimeric Antigen Receptors and Endogenous T Cell Receptors","volume":"130","author":"Kohler","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.019_bib46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2567.2012.03579.x","article-title":"Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign","volume":"136","author":"Andreatta","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3","article-title":"Telomerase activity in human germline and embryonic tissues and cells","volume":"18","author":"Wright","year":"1996","journal-title":"Dev. Genet."},{"key":"10.1016\/j.ymthe.2020.11.019_bib48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm.2128","article-title":"Lethal graft-versus-host disease in mouse models of T\u00a0cell receptor gene therapy","volume":"16","author":"Bendle","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.019_bib49","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2012-11-465971","article-title":"Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia","volume":"121","author":"Miyazaki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.019_bib50","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-15-2318","article-title":"Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies","volume":"76","author":"Sandri","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.11.019_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T\u00a0cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2020.11.019_bib52","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2020.11.019_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib54","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40264-018-0779-3","article-title":"Safety and Tolerability of Adoptive Cell Therapy in Cancer","volume":"42","author":"Wolf","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2020.11.019_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0167-5699(93)90264-L","article-title":"Natural history of HLA expression during tumour development","volume":"14","author":"Garrido","year":"1993","journal-title":"Immunol. Today"},{"key":"10.1016\/j.ymthe.2020.11.019_bib57","doi-asserted-by":"crossref","first-page":"14896","DOI":"10.1038\/srep14896","article-title":"Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses","volume":"5","author":"Matsuzaki","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.11.019_bib58","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1038\/cti.2017.37","article-title":"Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T\u00a0cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes","volume":"6","author":"Li","year":"2017","journal-title":"Clin. Transl. Immunology"},{"key":"10.1016\/j.ymthe.2020.11.019_bib59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/icb.2016.14","article-title":"Tumour-specific CD4 T\u00a0cells eradicate melanoma via indirect recognition of tumour-derived antigen","volume":"94","author":"Shklovskaya","year":"2016","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2020.11.019_bib60","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/art.1780360614","article-title":"Spontaneous production of Epstein-Barr virus by B lymphoblastoid cell lines obtained from patients with Sj\u00f6gren\u2019s syndrome. Possible involvement of a novel strain of Epstein-Barr virus in disease pathogenesis","volume":"36","author":"Tateishi","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymthe.2020.11.019_bib61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-0039.1992.tb01951.x","article-title":"DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA","volume":"40","author":"Kimura","year":"1992","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ymthe.2020.11.019_bib62","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1038\/s41598-017-11126-y","article-title":"A TCR-based Chimeric Antigen Receptor","volume":"7","author":"Walseng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.11.019_bib63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T\u00a0cells in a xenograft mouse model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.019_bib64","doi-asserted-by":"crossref","first-page":"e1302631","DOI":"10.1080\/2162402X.2017.1302631","article-title":"T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in\u00a0vivo tumor growth","volume":"6","author":"Inderberg","year":"2017","journal-title":"OncoImmunology"}],"updated-by":[{"DOI":"10.1016\/j.ymthe.2026.09.027","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000}}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:00:47Z","timestamp":1761501647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620306171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1525001620306171"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}